MAPT and Alzheimer disease: Furthermore, specificity of binding was demonstrated by double labelling of the AD tau fibrils with E2814 and Tau-5 antibody (Fig. 4 f) and complete absence of immunogold labelling with the IgG control antibody (Fig. 4 e + i).